Chiome Bioscience Balance Sheet Health
Financial Health criteria checks 5/6
Chiome Bioscience has a total shareholder equity of ¥1.2B and total debt of ¥303.0M, which brings its debt-to-equity ratio to 24.9%. Its total assets and total liabilities are ¥1.7B and ¥478.2M respectively.
Key information
24.9%
Debt to equity ratio
JP¥303.00m
Debt
| Interest coverage ratio | n/a |
| Cash | JP¥1.24b |
| Equity | JP¥1.22b |
| Total liabilities | JP¥478.23m |
| Total assets | JP¥1.69b |
Financial Position Analysis
Short Term Liabilities: 4583's short term assets (¥1.6B) exceed its short term liabilities (¥423.2M).
Long Term Liabilities: 4583's short term assets (¥1.6B) exceed its long term liabilities (¥55.0M).
Debt to Equity History and Analysis
Debt Level: 4583 has more cash than its total debt.
Reducing Debt: 4583's debt to equity ratio has increased from 0% to 24.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4583 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 4583 has sufficient cash runway for 1 years if free cash flow continues to grow at historical rates of 8.4% each year.